KITOV PHARMA LT/S (NASDAQ:KTOV) shares were up 2.1% during trading on Tuesday . The stock traded as high as $0.80 and last traded at $0.79, approximately 23,278 shares traded hands during trading. A decline of 80% from the average daily volume of 115,971 shares. The stock had previously closed at $0.77.
Several research analysts have commented on KTOV shares. Zacks Investment Research upgraded KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. ValuEngine upgraded KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Monday, May 20th.
The stock has a fifty day simple moving average of $0.91. The stock has a market cap of $12.45 million, a P/E ratio of 2.03 and a beta of 3.72.
About KITOV PHARMA LT/S (NASDAQ:KTOV)
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
Featured Story: Sell-Side Analysts
Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.